Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | Recent advances in the management of STS

Patrick Schöffski • 9 Sep 2022
ESMO 2022
Sarcoma

Patrick Schöffski, MD, MPH, KU Leuven, Leuven, Belgium, discusses treatment strategies for soft tissue sarcomas (STS), highlighting heterogeneity of the disease as well as recent advances in the identification of molecular drivers of STS. Prof. Schöffski touches on the development of MDM2-targeting agents as a potential therapeutic avenue for this patient population. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

More from Patrick Schöffski

2:02
Phase I dose-escalation and expansion study evaluating BI 907828 in patients with solid tumours
Patrick Schöffski • 9 Sep 2022
0:51
BI 907828: targeting MDM2 in solid tumors
Patrick Schöffski • 9 Sep 2022

Related Videos

0:51
Enhanced NK-cells in stage 4 sarcoma treatment
Vaishali Kumar • 8 Apr 2024
1:12
Predictive biomarkers for checkpoint inhibitors in sarcomas
Nadia Omelchenko • 8 Apr 2024
1:26
SAINT and LINNOVATE: combining ICIs and chemotherapy in advanced STC
Nadia Omelchenko • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals